Scholarlink

Purpose <p>Parathyroid carcinoma is a rare endocrine malignancy. This study aimed to evaluate the clinical characteristics, treatment approaches, and follow-up data of patients diagnosed with parathyroid carcinoma. Additionally, pathological findings were reassessed according to the 2022 World Health Organization (WHO) classification to examine its clinical implications.</p> Methods <p>The medical records of patients who were pathologically diagnosed with parathyroid carcinoma at the Endocrinology Clinic of a University Hospital between March 2013 and June 2024 were retrospectively reviewed. Clinical characteristics, demographic data, and laboratory findings were recorded. Pathological features were also obtained retrospectively from medical charts and records.</p> Results <p>We reported eight patients with surgical and pathological diagnoses of parathyroid carcinoma. Six of the patients were females and two were males. The ages of the patients ranged from 43 to 85, with a mean age of 61. The follow-up periods after diagnosis varied from 6 to 132 months. The calcium levels at diagnosis ranged from 11.7&#xa0;mg/dL to 18.4&#xa0;mg/dL, with a median of 16.0&#xa0;mg/dL (normal range 8.6–10.2&#xa0;mg/dL). The median PTH level at admission was 1609 ng/L (487.7–3035 ng/L) (normal range: 15–65 ng/L). Re-evaluation of all patients based on the 2022 WHO classification revealed no changes in initial diagnoses.</p> Conclusions <p>Surgical resection remains the cornerstone of effective treatment. Accurate preoperative assessment, including detailed clinical and biochemical evaluation, is essential for optimal management. Sharing comprehensive data with pathologists enhances diagnostic accuracy. This study emphasizes the relevance of preoperative indicators and highlights that the updated WHO classification supports existing diagnostic criteria without altering clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Revisiting parathyroid carcinoma through the lens of the 2022 WHO classification

  • 期刊论文

  • 发表日期：

    2026年4月29日

查看全文
  • Esma Pehlivan Koroglu,
  • Gokcen Unal Kocabas,
  • Yesim Ertan,
  • Murat Ozdemir,
  • Ilgin Yildirim Simsir,
  • Pinar Banu Sarer Yurekli

摘要

Purpose

Parathyroid carcinoma is a rare endocrine malignancy. This study aimed to evaluate the clinical characteristics, treatment approaches, and follow-up data of patients diagnosed with parathyroid carcinoma. Additionally, pathological findings were reassessed according to the 2022 World Health Organization (WHO) classification to examine its clinical implications.

Methods

The medical records of patients who were pathologically diagnosed with parathyroid carcinoma at the Endocrinology Clinic of a University Hospital between March 2013 and June 2024 were retrospectively reviewed. Clinical characteristics, demographic data, and laboratory findings were recorded. Pathological features were also obtained retrospectively from medical charts and records.

Results

We reported eight patients with surgical and pathological diagnoses of parathyroid carcinoma. Six of the patients were females and two were males. The ages of the patients ranged from 43 to 85, with a mean age of 61. The follow-up periods after diagnosis varied from 6 to 132 months. The calcium levels at diagnosis ranged from 11.7 mg/dL to 18.4 mg/dL, with a median of 16.0 mg/dL (normal range 8.6–10.2 mg/dL). The median PTH level at admission was 1609 ng/L (487.7–3035 ng/L) (normal range: 15–65 ng/L). Re-evaluation of all patients based on the 2022 WHO classification revealed no changes in initial diagnoses.

Conclusions

Surgical resection remains the cornerstone of effective treatment. Accurate preoperative assessment, including detailed clinical and biochemical evaluation, is essential for optimal management. Sharing comprehensive data with pathologists enhances diagnostic accuracy. This study emphasizes the relevance of preoperative indicators and highlights that the updated WHO classification supports existing diagnostic criteria without altering clinical practice.